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Abstract
The beneficial effects of cocoa on vascular function are mediated by the absorption of monomeric flavanols into the circulation from the
small intestine. As such, an understanding of the impact of the food matrix on the delivery of flavanols to the circulation is critical in asses-
sing the potential vascular impact of a food. In the present study, we investigated the impact of carbohydrate type on flavanol absorption
and metabolism from chocolate. A randomised, double-blind, three-arm cross-over study was conducted, where fifteen volunteers were
randomly assigned to either a high-flavanol (266 mg) chocolate containing maltitol, a high-flavanol (251 mg) chocolate with sucrose or
a low-flavanol (48 mg) chocolate with sucrose. Test chocolates were matched for micro- and macronutrients, including the alkaloids theo-
bromine and caffeine, and were similar in taste and appearance. Total flavanol absorption was lower after consumption of the maltitol-
containing test chocolate compared with following consumption of its sucrose-containing equivalent (P¼0·002). Although the
O-methylation pattern observed for absorbed flavanols was unaffected by sugar type, individual levels of unmethylated (2)-epicatechin
metabolites, 30-O-methyl-epicatechin and 40-O-methyl-epicatechin metabolites were lower for the maltitol-containing test chocolate
compared with the sucrose-containing equivalent. Despite a reduction in the total plasma pool of flavanols, the maximum time (Tmax)
was unaffected. The present data indicate that full assessment of intervention treatments is vital in future intervention trials with flavanols
and that carbohydrate content is an important determinant for the optimal delivery of flavanols to the circulation.
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Evidence suggests that the regular consumption of diets rich in
fruit and vegetables and/or beverages, such as tea and wine,
may have cardiovascular benefits(1–4) and that flavonoids
contained within these foods may be the components respon-
sible for function(4–10). Cocoa and cocoa-based products, such
as chocolate, are a potentially rich source of one flavonoid
subgroup called flavanols(11), and in certain settings, these
foods have been found to be important contributors to the
total dietary intake of flavonoids(5). Although the health
benefits of flavanols in humans are accumulating, there is
insufficient evidence to claim a clear and undisputed positive
health effect relating to their consumption, particularly with
regard to long-term ingestion and health. In addition, choco-
late products are usually rich in sugar and saturated fats,
which might counteract the beneficial effects exerted by the
flavanols they contain. At present, much of the strongest
data, particularly with regard to cardiovascular benefits, are
based on short-term, small-scale human studies; where appro-
priate, well-characterised controls have been utilised.
Considering the limitations mentioned above, cocoa-
derived flavanols have been shown to be capable of promot-
ing clinically significant improvements in cardiovascular
health through their potential to lower blood pressure(7,12–15),
improve endothelial function(16–21), inhibit platelet aggrega-
tion(22–24) and curtail the inflammatory response(25–27)
following oral intake. As such, there has been much interest
in understanding the factors that define the liberation (from
foods), absorption, metabolism, distribution and excretion of
flavanols in vivo (19,28–34), in order to better understand the
bioavailability of flavanols in the context of different food
matrices, and ultimately, to enable improved food design for
health. An important aspect of flavanol delivery relates to
the influence of the food matrix on the liberation of flavanols
from the food before absorption. For example, the physical
*Corresponding author: Dr J. P. E. Spencer, email j.p.e.spencer@reading.ac.uk
Abbreviations: 3ME, 30-O-methyl-epicatechin; 4ME, 40-O-methyl-epicatechin; CF, cocoa flavanol.
British Journal of Nutrition (2012), 108, 2243–2250 doi:10.1017/S0007114512000475
q The Authors 2012
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
composition of the cocoa-containing product might have an
impact on plasma flavanol kinetics(32). While the majority of
the published literature on the effects of food matrices on
cocoa flavanol (CF) absorption has focused on the influence
of dairy products on absorption and metabolism(34,35–38),
there has also been interest in the impact of carbohydrates
on the biotransformation of flavanols. Indeed, the extent,
and rate, of flavanol absorption appears to be affected by
concurrent consumption of bread, sugar or grapefruit juice,
whereas no specific protein–flavanol or lipid–flavanol
interactions have been reported with respect to flavanol
absorption/metabolism(29). In addition, co-administration of
flavanols with carbohydrate-rich foods appears to lead to a
significant increase in plasma flavanol concentrations and an
acceleration of their renal elimination(29). While these results
suggest that the presence of carbohydrate in the food matrix
may increase overall flavanol absorption, these studies were
not designed to specifically assess the impact of sugar on
flavanol absorption. The present study has been designed to
specifically investigate the impact of sugar type by use of
two solid chocolates matched for physical structure, lipid,
milk and flavanol content but differing in that one contains
sucrose and the other the carbohydrate substitute, maltitol.
Experimental
Materials
Unless otherwise stated, all chemicals and reagents were
obtained from Sigma-Aldrich Company Limited or Thermo
Fisher Scientific. Flavanol standards were a gift from Mars,
Inc. Specialised HPLC solvents were purchased from Hichrom
and HPLC columns were from Phenomenex.
Flavanol-containing test chocolates
The test chocolates were in the form of solid chocolate bars,
which were supplied by Mars, Inc. The serving size of each
bar was 25 g. All test chocolates were standardised for their
total CF content and profile, and aside from the energy and
carbohydrate content of the maltitol product, all test products
were closely matched for equal macro- and micronutrient
content, energy load, and theobromine and caffeine levels
(Table 1). All chocolate bars were similar in taste and were
supplied individually wrapped and labelled with a random
three-digit code. Each 25 g serving contained 48 mg (low-CF,
sugar-sweetened chocolate), 251mg (high-CF, sugar-sweetened
chocolate) or 266mg (high-CF, maltitol-sweetened chocolate) of
total CF. The amount of total CF is defined as the sum of all
monomeric flavanols and their oligomeric (dimer to decamer)
derivatives (Table 1). The amount of epicatechin, the major
flavanol monomer, present in the chocolates was 8mg for the
low-CF sweetened chocolate, 54mg for the high-CF sweetened
chocolate and 58mg for the high-CF, maltitol-sweetened choco-
late. In addition to the added sugar reported, a small amount
of endogenous carbohydrate from the chocolate liquor is present
in all the chocolate bars.
Intervention study subjects
A total of fifteen healthy volunteers (nine women and six
men) with a mean age of 26·9 (SEM 3·4) years and a BMI
between 18·1 and 26·9 kg/m2 (mean BMI 22·7 (SEM 3·5) kg/m2)
were recruited. All female volunteers were self-reported pre-
menopausal (stable and regular menstrual cycles). Volunteers
were assessed before the start of the trial for good health and
were selected according to certain inclusion and exclusion cri-
teria. Inclusion criteria for participation in the study were as
follows: signed consent form; aged between 18 and 40
years; in good general health; not pregnant or lactating; no
allergy to milk products or sensitivity to alkaloids/caffeine;
no gastrointestinal disorders (e.g. chronic constipation, diar-
rhoea, inflammatory bowel disease, irritable bowel syndrome
or other chronic gastrointestinal complaints); not diabetic or
suffering from hypertension (140/90 mmHg); no anaemia
Table 1. Compositional analysis of the cocoa flavanol bars
Analysis
Sucrose
low-flavanol bar
Sucrose
high-flavanol bar
Maltitol
high-flavanol bar
Energy values (kcal/100 g) 519 516 445
Energy values (kJ/100 g) 2163 2149 1839
Protein (g/100 g) 8·10 8·46 8·44
Fat (g/100 g) 35·3 34·5 34·3
Carbohydrates (g/100 g) 42·4 43·0 43·1
Sugars (g/100 g) 39·0–39·4 39·0–39·4 0·5–0·9
Sucrose (g/100 g) 39·0 39·0 0·5
Polyols (g/100 g) – – 43·5–46·0
Maltitol (g/100 g) – – 43·5
Fibres (g/100 g) 9·2 8·8 8·9
Moisture (g/100 g) 1·00 1·11 1·20
Ash (g/100 g) 3·18 2·41 2·21
Na (mg/100 g) 5·1 2·2 2·1
Caffeine (mg/100 g) 58 102 102
Theobromine (mg/100 g) 643 709 710
Cocoa flavanols (mg/100 g) 190 1005 1064
Epicatechin (mg/100 g) 32 216 232
Catechin (mg/100 g) 28 84 92
Procyanidin oligomers
(dimers to decamers) (mg/100 g)
130 705 740
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or gall bladder problems. Exclusion criteria were as follows:
those on a weight-reducing dietary regimen; taking any diet-
ary supplements; consuming more than fifteen units (120 g)
of alcohol per week; taking anti-inflammatory or blood press-
ure-lowering medication; smokers or those with sensitivities to
chocolate, reduced-energy sweeteners, dairy products, nuts or
gluten; vegetarians or vegans. Volunteers were instructed not
to alter their usual dietary or fluid intakes during their partici-
pation in the study. Those selected were required to refrain
from the following for 24 h before the start of the study: con-
sumption of flavonoid-rich foods including many fruits and
vegetables, cocoa, chocolate, tea, coffee and alcohol, and
were provided with a low-flavonoid meal (low-fat macaroni
cheese) for consumption the evening before the study days.
Study design
The study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures invol-
ving human subjects were approved by the University of
Reading Research Ethics Committee (reference no. 08/08).
The study was also registered with the National Institutes of
Health-randomised trial records held on the National Institutes
of Health ClinicalTrials.gov website (NCT01292967). The study
was a randomised, double-blind, three-arm cross-over study
design and consisted of three intervention arms of 5 h each,
separated by a 1-week washout period. Each arm was pre-
ceded by a 24 h low-flavonoid diet and subjects were asked
to fast for 12 h before each intervention day. During each
intervention period, participants consumed a high-flavanol
chocolate containing maltitol, a high-flavanol chocolate
containing sucrose or a low-flavanol chocolate containing
sucrose. The order of administration was randomly assigned.
On each study day, subjects were cannulated and baseline
blood samples were collected. After consumption of the test
chocolate, blood samples (20 ml) were collected at 1, 2 and
4 h post-consumption. All chocolates were well tolerated by
the volunteers and there were no reports of gastrointestinal
problems related to the ingestion of any of the products,
including the maltitol-containing product. Indeed, total malti-
tol ingestion was approximately 10 g, which was below the
40 g where adverse gastrointestinal effects have been
reported(39).
Plasma sample preparation
Due to the lack of authentic flavanol metabolite standards,
plasma samples were prepared using enzymatic hydrolysis
with b-glucuronidase and sulfatase, as described previously(40).
After enzymatic hydrolysis, glucuronidated and sulphated
flavanols were converted into unmethylated, 30-O-methylated
and 40-O-methylated flavanol metabolites. To ensure that
the hydrolysis of the flavanol metabolites was complete, this
procedure was validated with the use of 4-nitrophenyl-
b-D-glucuronic acid and nitrocatechol sulphate (data not
shown). The validation with authentic flavanol standards has
also been reported previously(40). Briefly, blood samples
were immediately processed to isolate plasma and ascorbic
acid (1 mg/ml) was added to each before storage (at 280 8C).
Before analysis, 1 ml of plasma was defrosted on ice and
subjected to b-glucuronidase and sulfatase treatment
(10 000 units b-glucuronidase, 300 units sulfatase, 40 min;
378C) to produce non-glucuronidated and non-sulphated
metabolites for analysis. Then, samples were mixed with
2 ml of acidified ice-cold methanol (0·5 % acetic acid in
methanol, v/v) containing 30-O-ethyl-(2)-epicatechin (500 nM)
as a recovery standard. Samples were centrifuged at 17 000 g
for 15 min at 48C and the supernatant was collected. The
pellet was extracted again with 2 ml of acidified ice-cold
methanol (0·5 % acetic acid in methanol, v/v) containing
30-O-ethyl-(2)-epicatechin (500 nM), and then with 1 ml of
50 % methanol acidified with 0·5 % acetic acid and containing
30-O-ethyl-(2)-epicatechin (500 nM). Combined supernatants
underwent concentration (to approximately 50ml) using a
Speedvac system (Thermo Fisher Scientific, Inc.) and were
mixed with resorcinol (300 pmol) and catechol (300 pmol)
(internal standards) before analysis by HPLC.
Flavanol quantification by HPLC-fluorescence
detection/UV
Plasma samples were analysed for flavanol metabolites by the
HPLC-fluorescence detection/UV technique, as described
previously(40). Flavanol monomers and O-methylated
metabolites were analysed using a Hewlett-Packard 1200
series HPLC (Hewlett-Packard) equipped with a diode array
and fluorescence detector. Samples (50ml) were injected
onto a reversed-phase Phenomenex Luna C18(2) column
(4·6 £ 150 mm) with 3mm particle size. The mobile phase con-
sisted of (A) HPLC-grade water, (B) 200 mM-sodium acetate
(pH 4·4)–methanol (84:16) and (C) acetonitrile, and the
following gradient protocol was run: 0 min, 75 % A, 25 % B;
5 min, 75 % A, 25 % B; 20 min, 65 % A, 25 % B; 28 min, 63 %
A, 25 % B; 34 min, 55 % A, 25 % B; 41 min, 45 % A, 25 % B;
45 min, 25 % B, 75 % C; 55 min, 25 % B, 75 % C; 56·1 min,
75 % A, 25 % B; 60 min, 75 % A, 25 % B. The flow rate was
0·8 ml/min. Detection of flavanols and their metabolites was
performed using a fluorescence detector with an excitation
wavelength of 276 nm and an emission wavelength of
316 nm. The concentration of each compound was deter-
mined using an external calibration curve produced with the
use of authentic standards.
Statistical analysis
Mixed models were fitted to analyse the data using
SAS version 9.1 (SAS Institute). The outcome variables were
epicatechin, 30-O-methyl-epicatechin (3ME) and 40-O-methyl-
epicatechin (4ME). The subject was considered a random
effect to explain the correlation of the observations at different
times within subjects. For 3ME, a logarithmic transformation
was needed in order to validate the model. For 4ME, a
Box–Cox transformation was applied with a ¼ 0·3 (the out-
come variable 4ME was transformed to 4ME0·3). The AUC
and the peak plasma concentration of flavanols (maximum
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concentration, Cmax) were calculated according to non-
compartmental models.
Results
No flavanols were detected in the plasma samples of any of
the subjects at baseline or following the consumption of the
low-flavanol chocolate, suggesting that all volunteers com-
plied with the 24 h low-flavonoid diet before the study day
(Fig. 1). Unmethylated epicatechin, 3ME and 4ME metabolites
were detected in all plasma samples of subjects who had
consumed either of the high-flavanol test chocolates (Figs. 1
and 2). In contrast, no catechin, 30-O-methyl-catechin or
40-O-methyl-catechin metabolites were detected following
the consumption of any of the test chocolates. The plasma
levels of unmethylated epicatechin metabolites (P¼0·0002),
3ME (P¼0·0304) and 4ME (P¼0·0397) metabolites were
significantly higher at 1 and 2 h after consumption of the
sugar-containing test chocolate compared with following
the consumption of the maltitol-containing test chocolate
(Fig. 2). Furthermore, consumption of the sucrose-containing
test chocolate resulted in a 19 % higher total AUC and 17 %
higher Cmax for plasma unmethylated epicatechin compared
with its maltitol equivalent (Table 2). However, this was not
the case for 3ME or 4ME derivatives, where there were no
significant differences (P.0·05). There was no significant
difference in the maximum time (Tmax) between the two
high-flavanol containing test chocolates with respect to
epicatechin, 3ME and 4ME (P.0·05; Table 2).
The differences in absorption characteristics between the
sucrose-containing and maltitol-containing chocolates were
also reflected in the total plasma flavanol levels (Fig. 3). At 1
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Fig. 1. HPLC chromatograms of (a) standards of unmethylated (peak 1), 30-O-methylated (peak 2) and 40-O-methylated (peak 3) (2 )-epicatechin and the recovery
standard 30-O-ethyl-(2 )-epicatechin (peak 4); enzymatic treated plasma samples (b) before and (c) after 2 h of consumption of the sugar-containing high-flavanol
chocolate bar. Detection of flavanol metabolites was performed using a fluorescence detector with an excitation wavelength of 276 nm and an emission wave-
length of 316 nm.
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and 2 h post-consumption, the total plasma flavanol concen-
trations were 26 and 17 % higher, respectively, after consump-
tion of the sucrose-containing chocolate compared with
following the maltitol-containing one (P¼0·0001 and
P¼0·0102, respectively). However, this difference was no
longer evident at 4 h post-consumption (P¼0·6830).
Discussion
The general kinetics of absorption, metabolism and plasma
concentration of flavanols reported here are consistent with
previous studies using similar chocolate/cocoa interven-
tions(19,41–44). However, despite these similarities, there were
significant differences in the relative absorption of flavanols
as a function of the type of chocolate product consumed.
The sugar alcohol maltitol is a commonly used sucrose
alternative, as it delivers less energy per g (8·8 kJ/g (2·1 kcal/g)
compared with 16·8 kJ/g (4·0 kcal/g)) and does not contribute
to tooth decay(45). The present data indicate that consumption
of flavanols in a product containing maltitol rather than sucrose
results in a significantly lower level of total flavanol absorption
and a lower peak plasma concentration of unmethylated epica-
techin metabolites. As the primary difference between the two
high-flavanol-containing test chocolates used in the present
study was their carbohydrate content and thus their total
energy load (Table 1), the present data suggest that the
carbohydrate composition of the food matrix is an important
determinant for total flavanol absorption in the small intestine.
However, carbohydrate type and/or energy did not have a
significant impact on the O-methylation pattern observed for
absorbed flavanols, suggesting that while total absorption was
affected, catechol-O-methyltransferase metabolic activity was
unchanged. Previous investigations into the influence of
carbohydrate on flavanol absorption were inconclusive(29,32),
primarily due to the use of inadequate control interventions or
the relatively low amounts of flavanols in the test materials.
With respect to the latter, flavanol absorption appears to be
influenced by the food matrix to a greater degree if flavanol
levels are low (6·7 mg epicatechin, 70 mg procyanidins per
cocoa drink)(28). However, in the case of most commercially
available dark chocolates, the level of CF is indeed closer to
that used in the present study (54 mg epicatechin, 251 mg of
total CF per bar)(46,47).
A limitation of the present study is that plasma flavanols
were quantified only 4 h post-consumption. As such, it is
unclear whether plasma flavanol levels post-4 h would
follow the same profile. However, the maximum level of
plasma epicatechin metabolites was found between 1 and
2 h after flavanol intake, and by 4 h, plasma epicatechin
metabolites were low (Fig. 2), suggesting that it is unlikely
the plasma flavanol levels post-4 h will greatly contribute to
the total plasma flavanol load. The well-reported laxative
effect of maltitol may be one explanation for the decrease in
flavanol absorption(48), although no gastrointestinal problems
were reported among the volunteers of the present study.
Polyols undergo negligible absorption in the small intestine,
thus causing symptoms of gastrointestinal intolerance, such
as increased intestinal transit times, bloating or diarrhoea(49).
Despite this, maltitol, when used at a dose three times
higher than the present study (30 g), has been found not to
induce gastrointestinal symptoms(39,48,50). Nevertheless, malti-
tol may act to limit flavanol absorption due to its effect on the
osmolarity of the small-intestinal contents. In the jejunum,
nutrient absorption is the major driving force for water absorp-
tion(51) and non-absorbable solutes that remain within the
intestinal lumen produce an osmotic pressure that may limit
water absorption. For example, lactulose, a non-digestible
sugar commonly used as a laxative, has been shown to
impair drug absorption in healthy volunteers, something that
was partially reversed by the co-administration of sucrose(51).
Maltitol has previously been reported to reduce the absorption
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Fig. 2. (a) Unmethylated, (b) 30-O-methylated and (c) 40-O-methylated
epicatechin metabolites in the plasma before (0 h) and after (1, 2 and 4 h)
consumption of the sugar-containing ( ) and maltitol-containing ( )
high-flavanol chocolate bar. Values are mean plasma concentrations, with
their standard errors represented by vertical bars (n 15). *,** Mean values
were significantly different for non-methylated epicatechin (P¼0·002),
30-O-methyl-epicatechin (P¼0·0304) and 40-O-methyl-epicatechin (P¼0·0397)
plasma metabolites between the sugar-containing and maltitol-containing
high-flavanol chocolate bars.
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of nutrients in the small intestine(52), thus the absorption of
flavanols may also be affected by the presence of maltitol.
Lastly, although the absorption of flavanols, and, indeed,
other flavonoids, is considered to occur by a process of pas-
sive absorption(53,54), we cannot rule out that the greater
amount of energy delivered with the sugar-containing food
may have an impact on metabolic events in enterocytes,
thus facilitating greater transfer from the lumen to the portal
blood. Further research is needed to elucidate the precise
mechanisms by which maltitol limits the absorption of CF in
the small intestine.
As the vascular benefits of flavanol-containing foods
are dependent on the delivery of flavanols to the systemic
circulation(21,31,18,55), factors affecting their absorption and
metabolism, including food matrix components such as
carbohydrate, represent important considerations in the
design of new products aimed to support cardiovascular
health. However, while the present data suggest that the use
of a replacement sugar, such as maltitol, may reduce flavanol
absorption, at present, it is unclear as to whether this approxi-
mate 20 % reduction in flavanol absorption would have an
impact on beneficial vascular responses. Although plasma
flavanol levels were not measured, previous data suggest
that sugar-free cocoa may improve endothelial function in
overweight adults to a greater degree than regular or sugar-
sweetened cocoa(31,56). While this result may appear to be
counter-intuitive to the present findings, there is also clear
evidence that flavanol-induced improvements in endothelial
function are dose-dependent with respect to plasma levels
of (2)-epicatechin(18). Furthermore, sugar-free cocoa might
be expected to induce a greater vascular effect than a
maltitol-containing equivalent, as it would not be expected
to influence intestinal osmolarity and thus flavanol absorption.
Further work is warranted in order to investigate the impact
of low-energy, sucrose replacements on the vascular efficacy
of a food in addition to its effects on the absorption of CF.
Despite the findings reported here and elsewhere in the
literature, from the point of view of public health nutrition,
recommending chocolate consumption, as part of a healthy
diet, is controversial, as chocolate, while potentially high in
flavanols, is also high in sugar and saturated fats. An increase
in chocolate consumption might lead to detrimental effects in
cardiovascular health and increases in body weight. As such,
any future exploitation of the health effects of CF requires
additional work in order to develop nutritionally responsible
food matrices designed with optimal flavanol delivery to the
vascular system in mind.
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